Cargando…
Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors
Angiogenesis is essential for tumor growth and metastasis. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor predominantly expressed in steroidogenic organs like the adrenal gland, ovary, testes, and placenta. EG-VEGF has antiapoptotic, mitogenic, and chemo...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630243/ https://www.ncbi.nlm.nih.gov/pubmed/26475302 http://dx.doi.org/10.1007/s12672-015-0236-z |
_version_ | 1782398667543543808 |
---|---|
author | Heck, Dorothee Wortmann, Sebastian Kraus, Luitgard Ronchi, Cristina L. Sinnott, Richard O. Fassnacht, Martin Sbiera, Silviu |
author_facet | Heck, Dorothee Wortmann, Sebastian Kraus, Luitgard Ronchi, Cristina L. Sinnott, Richard O. Fassnacht, Martin Sbiera, Silviu |
author_sort | Heck, Dorothee |
collection | PubMed |
description | Angiogenesis is essential for tumor growth and metastasis. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor predominantly expressed in steroidogenic organs like the adrenal gland, ovary, testes, and placenta. EG-VEGF has antiapoptotic, mitogenic, and chemoattractive properties mediated via the two G protein-coupled receptors prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2). We investigated the expression of EG-VEGF and its receptors in a large number of normal adrenal glands (NAG), adrenocortical adenomas (ACA), and carcinomas (ACC) using real-time PCR (NAG, n = 12; ACA, n = 24; and ACC, n = 30) and immunohistochemistry (NAG, n = 9; ACA, n = 23; and ACC, n = 163) and evaluated its impact on patients’ survival. EG-VEGF, PKR1, and PKR2 mRNA and protein are expressed in NAG and the vast majority of ACA and ACC samples. The mean EG-VEGF mRNA expression was significantly lower in ACC (606.5 ± 77.1 copies) compared to NAG (4,043 ± 1,111) and cortisol-producing adenomas (CPA) (4,433 ± 2,378) (p < 0.01 and p < 0.05, respectively). However, cytoplasmic and nuclear EG-VEGF protein expression was either significantly higher or similar in ACC (H score 2.4 ± 0.05, p < 0.05 and 1.7 ± 0.08, n.s., respectively) compared to NAG (1.8 ± 0.14 and 1.7 ± 0.2). Nuclear protein expression of either EG-VEGF or PKR1 or both is predictive for a higher mortality compared to patients without nuclear expression (hazard ratio (HR) = 5.15; 95 % confidence interval (CI) = 1.24–21.36, n = 100, p = 0.02 independent of age, sex, and tumor stage). These findings suggest that EG-VEGF and its receptor PKR1 might play a role in the pathogenesis of adrenocortical tumors and could serve as prognostic markers for this rare malignant disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12672-015-0236-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4630243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-46302432015-11-06 Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors Heck, Dorothee Wortmann, Sebastian Kraus, Luitgard Ronchi, Cristina L. Sinnott, Richard O. Fassnacht, Martin Sbiera, Silviu Horm Cancer Original Paper Angiogenesis is essential for tumor growth and metastasis. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor predominantly expressed in steroidogenic organs like the adrenal gland, ovary, testes, and placenta. EG-VEGF has antiapoptotic, mitogenic, and chemoattractive properties mediated via the two G protein-coupled receptors prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2). We investigated the expression of EG-VEGF and its receptors in a large number of normal adrenal glands (NAG), adrenocortical adenomas (ACA), and carcinomas (ACC) using real-time PCR (NAG, n = 12; ACA, n = 24; and ACC, n = 30) and immunohistochemistry (NAG, n = 9; ACA, n = 23; and ACC, n = 163) and evaluated its impact on patients’ survival. EG-VEGF, PKR1, and PKR2 mRNA and protein are expressed in NAG and the vast majority of ACA and ACC samples. The mean EG-VEGF mRNA expression was significantly lower in ACC (606.5 ± 77.1 copies) compared to NAG (4,043 ± 1,111) and cortisol-producing adenomas (CPA) (4,433 ± 2,378) (p < 0.01 and p < 0.05, respectively). However, cytoplasmic and nuclear EG-VEGF protein expression was either significantly higher or similar in ACC (H score 2.4 ± 0.05, p < 0.05 and 1.7 ± 0.08, n.s., respectively) compared to NAG (1.8 ± 0.14 and 1.7 ± 0.2). Nuclear protein expression of either EG-VEGF or PKR1 or both is predictive for a higher mortality compared to patients without nuclear expression (hazard ratio (HR) = 5.15; 95 % confidence interval (CI) = 1.24–21.36, n = 100, p = 0.02 independent of age, sex, and tumor stage). These findings suggest that EG-VEGF and its receptor PKR1 might play a role in the pathogenesis of adrenocortical tumors and could serve as prognostic markers for this rare malignant disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12672-015-0236-z) contains supplementary material, which is available to authorized users. Springer US 2015-10-16 /pmc/articles/PMC4630243/ /pubmed/26475302 http://dx.doi.org/10.1007/s12672-015-0236-z Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Heck, Dorothee Wortmann, Sebastian Kraus, Luitgard Ronchi, Cristina L. Sinnott, Richard O. Fassnacht, Martin Sbiera, Silviu Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors |
title | Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors |
title_full | Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors |
title_fullStr | Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors |
title_full_unstemmed | Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors |
title_short | Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors |
title_sort | role of endocrine gland-derived vascular endothelial growth factor (eg-vegf) and its receptors in adrenocortical tumors |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630243/ https://www.ncbi.nlm.nih.gov/pubmed/26475302 http://dx.doi.org/10.1007/s12672-015-0236-z |
work_keys_str_mv | AT heckdorothee roleofendocrineglandderivedvascularendothelialgrowthfactoregvegfanditsreceptorsinadrenocorticaltumors AT wortmannsebastian roleofendocrineglandderivedvascularendothelialgrowthfactoregvegfanditsreceptorsinadrenocorticaltumors AT krausluitgard roleofendocrineglandderivedvascularendothelialgrowthfactoregvegfanditsreceptorsinadrenocorticaltumors AT ronchicristinal roleofendocrineglandderivedvascularendothelialgrowthfactoregvegfanditsreceptorsinadrenocorticaltumors AT sinnottrichardo roleofendocrineglandderivedvascularendothelialgrowthfactoregvegfanditsreceptorsinadrenocorticaltumors AT fassnachtmartin roleofendocrineglandderivedvascularendothelialgrowthfactoregvegfanditsreceptorsinadrenocorticaltumors AT sbierasilviu roleofendocrineglandderivedvascularendothelialgrowthfactoregvegfanditsreceptorsinadrenocorticaltumors |